“Statistically significant and highly clinically meaningful” perhaps, but not so much that they can say what that actually means. My understanding is that of all cancer drugs approved by the FDA between 2000-2016 (around 90 drugs), the median life extension was just over 2 months...
The distribution skews right on these things. Median probably is not the right way to think about it
Two months was from clinical trials where there's no doubt that the "thumb is on the scale" in a host of ways, creating an exaggerated estimate of efficacy that would be realised in the real world.
The reality is closer to no life extension, with the remaining lifespan is spent sicker than you'd have been without the drugs.